Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Small Cell Lung Cancer Extensive Stage: early-phase trial registry
3 of 4 indexed Small Cell Lung Cancer Extensive Stage trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Small Cell Lung Cancer Extensive Stage: 4 US clinical trials tracked, 3 recruiting.
Small Cell Lung Cancer Extensive Stage is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Legend Biotech USA, running 1 of these trials.
Enrollment posture brief
Registry condition small-cell-lung-cancer-extensive-stage
OPEN 3 | RECR 75% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Small Cell Lung Cancer Extensive Stage lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Small Cell Lung Cancer Extensive Stage on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Small Cell Lung Cancer Extensive Stage is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Genprex
NCT05703971
Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
University of Texas Southwestern Medical Center
NCT07139990
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Legend Biotech USA
NCT05680922
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03923270
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Small Cell Lung Cancer Extensive Stage records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Small Cell Lung Cancer Extensive Stage trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Small Cell Lung Cancer Extensive Stage page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Small Cell Lung Cancer Extensive Stage trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Legend Biotech USA sponsors the most Small Cell Lung Cancer Extensive Stage trials on record, review their full trial history before evaluating a specific study. See Legend Biotech USA's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Small Cell Lung Cancer Extensive Stage condition card totals 4 registered trials; most-linked intervention Thoracic Radiotherapy; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.